Scientist, Cellular Models

1910 Genetics

20n Bio

3DBio Therapeutics

3T Biosciences

4D Molecular Therapeutics

64x Bio

8Biomed

A-Alpha Bio

A2 Biotherapeutics

AavantiBio

AB Studio

Abalone Bio

Abata Therapeutics

Abeona Therapeutics

Abintus Bio

Absci

Accelevir Diagnostics

Accent Therapeutics

ACELYRIN

Acepodia

Achieve Life Sciences

Acrivon Therapeutics

Acrotech Biopharma

Acutis Diagnostics

Adagio Therapeutics

Adaptive Phage Therapeutics

Adcentrx Therapeutics

Adicet Bio

adMare BioInnovations

Admera Health

Adverum Biotechnologies

adyn

Aeglea BioTherapeutics

Aether Bio

Affini-T Therapeutics

Affinia Therapeutics

Affinivax

AgBiome

Agena Bioscience

AiLife Diagnostics

Akero Therapeutics

Akouos

Alamar Biosciences

Alector

Aleo BME

AlivaMab Discovery Services

Alkahest

Alladapt Immunotherapeutics

Allakos

Allarta Life Science

Allay Therapeutics

AlloVir

Alloy Therapeutics

AllStripes

Alltrna

Alpine Immune Sciences

Altavant Sciences

Altis Biosystems

Alto Neuroscience

AltPep

Alumis

Alveo Technologies

ALX Oncology

Alzheon

Ambagon Therapeutics

Amberstone Biosciences

Ambys Medicines

Amylyx

AN2 Therapeutics

Anagenex

Analytical BioSciences

Andes

Angiocrine Bioscience

AnHeart Therapeutics

AnimalBiome

Annexon Biosciences

Antheia

Apollomics

Applied Molecular Transport

Aptevo Therapeutics

Apton Biosystems

Aptose Biosciences

Aqua Cultured Foods

Aquinnah Pharmaceuticals

Arbor Biotechnologies

Arcadia Science

Arcellx

Arcturus Therapeutics

Arcutis Biotherapeutics

Ardra

Arima Genomics

Ark Biotech

Arkuda Therapeutics

Armata Pharmaceuticals

Aro Biotherapeutics

Arpeggio Biosciences

Arrakis Therapeutics

Arranta Bio

ArsenalBio

Artisan Bio

Ascidian Therapeutics is creating gene therapies that replace exons via selective splicing of pre-mRNA. The technology is called RNA exon editing. A designer RNA is used to replace mutated, disease-causing exons within pre-mRNA. Multiple continuous exons can be replaced. This gene therapy approach allows editing large portions of RNA (rather than just single base changes), avoids the risks of direct DNA editing, and does not alter endogenous gene expression levels.

The company is named Ascidian, because their technology is based on a biological process that naturally occurs in ocean creatures called ascidians (also known as sea squirts). Ascidians use unique mechanisms of RNA splicing to re-engineer their transcriptome in developing from larvae to adults.

<p>Ascidian Therapeutics is creating gene therapies that replace exons via selective splicing of pre-mRNA. The technology is called RNA exon editing. A designer RNA is used to replace mutated, disease-causing exons within pre-mRNA. Multiple continuous exons can be replaced. This gene therapy approach allows editing large portions of RNA (rather than just single base changes), avoids the risks of direct DNA editing, and does not alter endogenous gene expression levels.</p>
<p>The company is named Ascidian, because their technology is based on a biological process that naturally occurs in ocean creatures called ascidians (also known as sea squirts). Ascidians use unique mechanisms of RNA splicing to re-engineer their transcriptome in developing from larvae to adults.</p>


Ascidian Therapeutics

Find a biotech startup* job.